Strikeforce Technologies Inc (OTCMKTS:SFOR) submitted Form 10-Q wherein it stated that revenue for the quarter closed March 31, 2016 came at $82,709 against the revenue of $68,661 in the previous year quarter. This jump in revenues can be attributed to the increase in maintenance sales, hardware sales, and sign on fees revenues. The company commenced selling its mobile products in outlets and enterprise accounts.
Strikeforce announced that they have opportunities, through its sales channels, that it projects, but cannot assure, will increase total revenues in FY2016. The management expects the revenue to grow as they introduce MobileTrust Ò.
Strikeforce reported that total revenue comprised of software and hardware sales, maintenance sales and services. It also covered revenue from recurring transaction fees and sign-on-fees revenues. Hardware sales for the quarter closed March 31, 2016 came at $810 compared to $0 in the same period, a year earlier. This growth in hardware revenues was a result of increased sales of key-fobs.
Software, maintenance sales and services for the quarter closed March 31, 2016 came at $81,899 against $68,661 for the quarter closed March 31, 2015. This jump in software, maintenance and services revenue can be attributed to the jump in the sales of company’s mobile products.
Strikeforce announced that cost of revenues in the reported period came at $906 against $736 for the quarter closed March 31, 2015. This jump was a result of increased sales of company’s one-time-password tokens. Gross profit for the quarter closed March 31, 2016 amounted to $81,803 against $67,925 in the same period, a year earlier. The jump in gross profit was mainly due to the rise in firm’s product revenues.
Strikeforce reported that R&D expenses jumped over 84% in the reported quarter. The company increased its technology team by recruiting a software engineer earlier in this year, which eventually resulted in higher R&D expenses.
OXIS International, Inc. (OTCMKTS:OXIS) Acquires Rights TO Develop TriKE
OXIS International, Inc. (OTCMKTS:OXIS) reported that it bought the rights to develop and commercialize a new technology, known as the Trispecific Killer Engager. This technology targets NK cells for the cancer treatment. The CEO, Anthony J. Cataldo, reported that this offers company with a noteworthy new asset. He revealed that the ‘TriKE’ technology has been assessed in pre-clinical models and demonstrated to be effective.
Growing pharmaceutical firms, within the oncology marketplace, have been focusing on the CAR-T therapies. OXIS is of view that there are certain adverse impacts linked to CAR-T therapies. It is primarily because the treatment works by rising toxicity inside the body. The CEO reported that TriKE gives an effective result, but not at the cost of rising toxicity levels within the body. OXIS plans to soon meet the FDA to get approval for clinical studies. At first, the trial would be aimed at identifying the efficacy and safety of the treatment.